Clinical Research Directory
Browse clinical research sites, groups, and studies.
TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors
Sponsor: Beijing GoBroad Hospital
Summary
This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-G203 in patients with GPC3-positive recurrent or metastatic solid tumors who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in solid tumors.
Official title: A Preliminary Clinical Study of TC-G203 for Patients With GPC3-Positive Recurrent/Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-12-18
Completion Date
2027-11-01
Last Updated
2026-01-21
Healthy Volunteers
No
Interventions
TC-G203 cells treatment
TC-G203 CAR-T cells Treatment follows a lymphodepletion Drug: Fludarabine and Cyclophosphamide.
Locations (2)
Beijing Gobroad Hospital
Beijing, Beijing Municipality, China
GoBroad Healthcare Group
Beijing, Beijing Municipality, China